Results 181 to 190 of about 538,702 (314)

Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways

open access: yesAdvanced Science, EarlyView.
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo   +16 more
wiley   +1 more source

NIR‐II Light‐Triggered Electron Flow Initiates Cuproptosis‐Centered Thermoelectric‐Immunotherapy for Breast Cancer

open access: yesAdvanced Science, EarlyView.
A NIR‐II light‐activatable thermoelectric nanoreactor converts surface‐bound Cu2+ into bioactive Cu+ via directed electron flow. This spatiotemporally controlled reduction triggers potent cuproptosis and immunogenic cell death, eradicating primary tumors and, together with aPD‐1 therapy, suppressing metastases while establishing durable immune memory ...
Boyu Yuan   +10 more
wiley   +1 more source

Renal Replacement Therapy in the Critically Ill Child*

open access: yesPediatric Critical Care Medicine, 2018
C. Westrope   +4 more
semanticscholar   +1 more source

RHINO: An Integrative Multi‐Omics Framework Linking Circadian Physiology to Precision Medicine

open access: yesAdvanced Science, EarlyView.
RHINO (RHythmic Interacting Network for multi‐Omics) is an integrative framework that maps circadian regulation across diverse genetic and disease contexts and prioritizes druggable circadian targets. Released as an AI‐powered interactive web portal, RHINO unifies genetic, regulatory, disease, and drug–target information, enabling context‐specific ...
Ying Chen   +12 more
wiley   +1 more source

EpCAM+ Extracellular Vesicle PD‐L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response

open access: yesAdvanced Science, EarlyView.
A highly sensitive SERS‐based platform measures PD‐L1 expression on EpCAM+ circulating EVs from cancer patients undergoing immunotherapy. Monitoring dynamic changes after treatment reveals that reduced EpCAM+ EV PD‐L1 levels associate with improved long‐term clinical outcomes, establishing a non‐invasive approach for tracking immune checkpoint ...
Byeonggeol Mun   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy